Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Wounds ; 32(8): 208-216, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-32804659

RESUMO

INTRODUCTION: Biofilm in chronic wounds impedes the wound healing process. Each biofilm has differing characteristics requiring a multifaceted approach for removal while maintaining a surrounding environment conducive to wound healing. OBJECTIVE: In this study, 3 of the components in a wound cleanser are tested to determine synergy in eradicating biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in vitro. MATERIALS AND METHODS: The 3 components assessed for synergy were ethylenediamine tetraacetic acid sodium salts (EDTA), vicinal diols (VD; ethylhexylglycerin and octane-1,2-diol), and polyhexamethylene biguanide (PHMB). Each component was assessed individually and in combination while dissolved in a base solution. The Calgary assay method was used for biofilm growth and treatment. Kull Equation analysis for synergy was conducted using viable count results. RESULTS: Synergy is defined as the interaction of components to produce a combined effect greater than the sum of their separate effects. The base solution containing all 3 components (EDTA, VD, and PHMB) reduced biofilm viability by more than 5 logs, demonstrating statistically significant synergy. The 3 components tested individually in the base solution resulted in the following: EDTA did not reduce bacteria viability; VD reduced viability by about 1 log; and PHMB reduced P aeruginosa viability by about 2.5 logs and MRSA viability by about 4 logs. Of importance, the MRSA biofilm failed to regrow in the recovery plates after combined treatment, indicating complete elimination of the biofilm bacteria. CONCLUSIONS: The experimental and calculated results indicate the 3 components (VD, EDTA, and PHMB) when used together act synergistically to eradicate MRSA and P aeruginosa biofilms in vitro.


Assuntos
Biguanidas/uso terapêutico , Biofilmes/efeitos dos fármacos , Detergentes/uso terapêutico , Ácido Edético/uso terapêutico , Éteres de Glicerila/uso terapêutico , Octanóis/uso terapêutico , Pele/efeitos dos fármacos , Ferimentos e Lesões/tratamento farmacológico , Biguanidas/administração & dosagem , Detergentes/administração & dosagem , Sinergismo Farmacológico , Ácido Edético/administração & dosagem , Éteres de Glicerila/administração & dosagem , Humanos , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Octanóis/administração & dosagem , Pseudomonas aeruginosa/efeitos dos fármacos , Pele/microbiologia , Ferimentos e Lesões/microbiologia
2.
Mov Disord ; 30(11): 1557-65, 2015 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-26293405

RESUMO

Although tremor is a highly prevalent movement disorder, progress in this field is limited because of the poor understanding of many of the underlying conditions. This review summarizes recent treatment attempts since 2013. For essential tremor, recent innovations are phase I or II studies of Octanol, several clinically relevant refinements for deep brain stimulation, and the development of the new magnetic resonance imaging guided focused ultrasound technique. Further new invasive and noninvasive electrical and magnetic stimulation techniques have been tested for essential tremor and parkinsonian tremor. For multiple sclerosis tremor, some open-label observations have shown positive results (natalizumab, dalfampridine, levetiracetam), whereas controlled trials using cannabinoids have been negative. Functional tremor has shown a positive response to retrainment. Neuroprosthetic devices have been tested in a variety of tremor conditions. Several promising medical and surgical treatment trials are underway and will be completed shortly.


Assuntos
Ensaios Clínicos como Assunto , Tremor/terapia , Estimulação Encefálica Profunda/métodos , Humanos , Próteses Neurais , Octanóis/uso terapêutico
3.
BMJ Clin Evid ; 20152015 Jan 14.
Artigo em Inglês | MEDLINE | ID: mdl-25587918

RESUMO

INTRODUCTION: Head louse infection is diagnosed by finding live lice, as eggs take 7 days to hatch (but a few may take longer, up to 13 days) and may appear viable for weeks after death of the egg. Infestation may be more likely in school children, with risks increased in children with more siblings or of lower socioeconomic group. Factors such as longer hair make diagnosis and treatment more difficult. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of physically acting treatments for head lice? We searched: Medline, Embase, The Cochrane Library, and other important databases up to March 2014 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found six studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: 1,2-octanediol, dimeticone, herbal and essential oils, and isopropyl myristate.


Assuntos
Antiparasitários/uso terapêutico , Infestações por Piolhos/tratamento farmacológico , Animais , Dimetilpolisiloxanos/uso terapêutico , Humanos , Miristatos/uso terapêutico , Octanóis/uso terapêutico , Óleos Voláteis/uso terapêutico , Pediculus , Resultado do Tratamento
4.
Orbit ; 32(6): 370-1, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23895342

RESUMO

PURPOSE: To report an unusual case of Demodex folliculitis presenting as periocular vesiculopustular rash. DESIGN: Case report. RESULTS: A 68 year-old woman presented with a unilateral periocular rash that was initially treated by her primary ophthalmologist with topical steroids and antivirals. Slit-lamp examination revealed severe bilateral blepharitis, right greater than left, with waxy sleeves around the eyelashes. The diagnosis of Demodex infestation was considered. Treatment with daily lid scrub with polyhexamethylene biguanide (PHMB), 1,2-hexanediol and 1,2-octanediol (OCuSOFT PLUS) and erythromycin ointment twice a day resulted in complete resolution of the symptoms after 4 weeks. CONCLUSIONS: Ophthalmologists should be aware of Demodex and consider it in the differential diagnosis of periocular skin lesions.


Assuntos
Blefarite/diagnóstico , Foliculite/diagnóstico , Infestações por Ácaros/diagnóstico , Ácaros , Dermatopatias Vesiculobolhosas/diagnóstico , Idoso , Animais , Antibacterianos/uso terapêutico , Biguanidas/uso terapêutico , Blefarite/tratamento farmacológico , Blefarite/parasitologia , Desinfetantes/uso terapêutico , Quimioterapia Combinada , Eritromicina/uso terapêutico , Feminino , Foliculite/tratamento farmacológico , Foliculite/parasitologia , Glicóis/uso terapêutico , Hexanos/uso terapêutico , Humanos , Infestações por Ácaros/tratamento farmacológico , Infestações por Ácaros/parasitologia , Octanóis/uso terapêutico , Pomadas , Dermatopatias Vesiculobolhosas/tratamento farmacológico , Dermatopatias Vesiculobolhosas/parasitologia
5.
PLoS One ; 7(4): e35419, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22523593

RESUMO

BACKGROUND: Interest in developing physically active pediculicides has identified new active substances. The objective was to evaluate a new treatment for clinical efficacy. METHODS AND FINDINGS: We describe the selection of 1,2-octanediol as a potential pediculicide. Clinical studies were community based. The main outcome measure was no live lice, after two treatments, with follow up visits over 14 days. Study 1 was a proof of concept with 18/20 (90%) participants cured. Study 2 was a multicentre, parallel, randomised, observer-blind study (520 participants) that compared 0.5% malathion liquid with 1,2-octanediol lotion (20% alcohol) applied 2-2.5 hours or 8 hours/overnight. 1,2-octanediol lotion was significantly (p<0.0005) more effective with success for 124/175 (70.9%) RR = 1.50 (97.5% CI, 1.22 to 1.85) for 2-2.5 hours, and 153/174 (87.9%) RR = 1.86 (97.5% CI, 1.54 to 2.26) for 8 hours/overnight compared with 81/171 (47.4%) for malathion. Study 3, a two centre, parallel, randomised, observer-blind study (121 participants), compared 1,2-octanediol lotion, 2-2.5 hours with 1,2-octanediol alcohol free mousse applied for 2-2.5 hours or 8 hours/overnight. The mousse applied for 8 hours/overnight cured 31/40 (77.5%), compared with 24/40 (60.0%) for lotion (RR = 1.29, 95% CI, 0.95 to 1.75; NNT = 5.7) but mousse applied for 2-2.5 hours 17/41 (41.5%) was less effective than lotion (RR = 0.69, 95% CI, 0.44 to 1.08). Adverse events were more common using 1,2-octanediol lotion at both 2-2.5 hours (12.0%, p = 0.001) and 8 hours/overnight (14.9%, p<0.0005), compared with 0.5% malathion (2.3%). Similar reactions were more frequent (p<0.045) using lotion compared with mousse. CONCLUSIONS: 1,2-octanediol was found to eliminate head louse infestation. It is believed to disrupt the insect's cuticular lipid, resulting in dehydration. The alcohol free mousse is more acceptable exhibiting significantly fewer adverse reactions. TRIAL REGISTRATIONS: Controlled-Trials.com ISRCTN66611560, ISRCTN91870666, ISRCTN28722846.


Assuntos
Infestações por Piolhos/tratamento farmacológico , Octanóis/uso terapêutico , Tensoativos/uso terapêutico , Adolescente , Adulto , Animais , Criança , Pré-Escolar , Feminino , Humanos , Masculino , Octanóis/administração & dosagem , Octanóis/efeitos adversos , Pediculus , Tensoativos/efeitos adversos
6.
Neurol Res ; 33(6): 614-24, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21708071

RESUMO

BACKGROUND: Reactive gliosis and scar formation after brain injury can inhibit the recovery process. As many glial cells utilize gap junctions for intercellular signaling, this study investigated whether two commonly used gap junction blockers, octanol and carbenoxolone, could attenuate reactive gliosis following a minor traumatic brain injury. METHODS: Octanol (710 mg/kg) or carbenoxolone (90 mg/kg) was administered 30 minutes before or after a needle track injury in adult male Sprague-Dawley rats. To mark dividing cells, animals were injected with bromodeoxyuridine (BrdU; 150 mg/kg) intraperitoneally two times per day, 8 hours apart and killed 2 days later. Immunohistochemistry for BrdU and markers for reactive glial cells [glial fibrillary acidic protein (GFAP), ED1, and NG2] were investigated using immunohistochemistry and western blot techniques. RESULTS: Two days after injury, increased cellular proliferation, activated astrocytes and microglia, and upregulation of NG2 expression were observed surrounding the injury site. Octanol and carbenoxolone administrated prior to injury significantly decreased cell proliferation by 60 and 70% respectively. The distance of GFAP immunoreactive astrocytes from the wound margin was decreased by 32 and 18% when octanol was administrated prior to or post injury respectively. Treatment with octanol also decreased the number of reactive microglia by 55% and, when administrated prior to injury, octanol reduced the distance of NG2 expression from the wound by 48%. CONCLUSION: The present study demonstrates that two important components of reactive gliosis, cellular activation and proliferation, can be attenuated by octanol and carbenoxolone.


Assuntos
Lesões Encefálicas/tratamento farmacológico , Carbenoxolona/uso terapêutico , Gliose/tratamento farmacológico , Octanóis/uso terapêutico , Animais , Animais Recém-Nascidos , Lesões Encefálicas/complicações , Lesões Encefálicas/patologia , Células Cultivadas , Gliose/etiologia , Gliose/patologia , Masculino , Ratos , Ratos Sprague-Dawley , Resultado do Tratamento
7.
Turk J Gastroenterol ; 22(6): 594-601, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22287404

RESUMO

BACKGROUND/AIMS: We aimed to investigate the hepatoprotective effects of dihydromyrcenol and geranyl formate extracted from the Vitis vinifera L. plant in a rat model of acute hepatic injury induced by carbon tetrachloride. METHODS: The study was performed on 54 Sprague-Dawley male rats. The animals were divided into 9 study groups with 6 rats in each. At the end of the 7-day study period, the animals were sacrificed. The effects of dihydromyrcenol and geranyl formate on hepatic injury were evaluated based on the comparisons of the changes in the weight, serum levels of alanine aminotransferase and aspartate aminotransferase, and histopathological changes in the liver. RESULTS: Dihydromyrcenol significantly reduced the carbon tetrachloride-associated ballooning degeneration and apoptotic cell counts; this reduction was moderate with low doses of geranyl formate, while no reductions were observed with high doses of geranyl formate. The changes in the alanine aminotransferase and aspartate aminotransferase levels were in accordance with these findings. CONCLUSIONS: It can be concluded that in an experimental model of acute hepatic injury induced by carbon tetrachloride, dihydromyrcenol presents a hepatoprotective effect, while geranyl formate presents partial hepatoprotective effects at low doses and no hepatoprotective effects at high doses.


Assuntos
Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle , Formiatos/uso terapêutico , Monoterpenos/uso terapêutico , Octanóis/uso terapêutico , Fitoterapia , Extratos Vegetais/uso terapêutico , Terpenos/uso terapêutico , Alanina Transaminase/sangue , Animais , Apoptose , Aspartato Aminotransferases/sangue , Peso Corporal , Tetracloreto de Carbono , Doença Hepática Induzida por Substâncias e Drogas/sangue , Doença Hepática Induzida por Substâncias e Drogas/patologia , Masculino , Ratos , Ratos Sprague-Dawley , Vitis
8.
Neurol Res ; 31(3): 238-44, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18671897

RESUMO

The role of gap junctional communication in the coordination of vascular behavior has been well established experimentally. The aim of this study was to investigate whether the gap junctional blockers would inhibit cerebral vasospasm after experimental subarachnoid hemorrhage (SAH). We used the double-hemorrhage model of SAH with injection of autologous arterial blood into the cisterna magna on days 1 and 2. Octanol or carbenoxolone was administered intracisternally on day 3, and repeated on days 4 and 5. Angiography was performed before (day 0) and 7 days after (day 7) SAH, and the diameter of the basilar artery was measured. Paraffin blocks of brain tissues were prepared and sectioned for hematoxylin and eosin staining for morphologic analysis. Arterial narrowing in SAH + octanol group and SAH + carbenoxolone group at day 7 was significantly less than that in SAH-only group and each SAH + vehicle group, respectively. Less morphologic changes in SAH + octanol group and SAH + carbenoxolone group were observed when compared to that in SAH-only group and each SAH + vehicle group. Western blotting showed that carbenoxolone down-regulated Cx43 protein expression in the BA, which in the SAH-only group was significantly higher than that of the normal group. Gap junction blockers attenuate the experimental cerebral vasospasm and down-regulate the increase in expression of Cx43 protein after SAH in rabbits. These data suggest that gap junctions play an important role in the development of cerebral vasospasm.


Assuntos
Artéria Basilar/anatomia & histologia , Carbenoxolona/uso terapêutico , Sinapses Elétricas/efeitos dos fármacos , Octanóis/uso terapêutico , Hemorragia Subaracnóidea/complicações , Vasoespasmo Intracraniano/tratamento farmacológico , Animais , Artéria Basilar/diagnóstico por imagem , Artéria Basilar/metabolismo , Conexina 43/metabolismo , Modelos Animais de Doenças , Regulação para Baixo/efeitos dos fármacos , Masculino , Coelhos , Radiografia , Distribuição Aleatória , Vasoespasmo Intracraniano/diagnóstico por imagem , Vasoespasmo Intracraniano/etiologia
9.
Eur J Cardiothorac Surg ; 34(2): 418-22, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18550382

RESUMO

OBJECTIVE: Anticalcification strategies of glutaraldehyde-fixed xenograft tissue aim to extract lipids or to neutralize toxic aldehyde residuals. The purpose of this study was to evaluate the efficacy of octanediol compared to standard treatments of glutaraldehyde-fixed bovine pericardium in the subdermal rat model. Octanediol treatment is an ethanolic solution (40%) containing a long chain aliphatic alcohol (5% 1,2-octanediol) that removes lipids without diminishing the stability of collagen. METHODS: Octanediol and standard glutaraldehyde fixed bovine pericardium were both implanted in 24 Sprague-Dawley rats, explanted after 30-75 days (12 animals each) and submitted to X-ray (score 0-4), histology, electron microscopy and elemental analysis by spectroscopy (Ca and P content). Unimplanted octanediol and standard glutaraldehyde fixed pericardium served as control. RESULTS: At 30 days octanediol-treated pericardium showed calcium content of 0.20+/-0.1 vs 20.07+/-36.79 mg/g dry weight for standard pericardium. The difference was also evident at 75 days: calcium content of 2.36+/-7.38 mg/g dry weight for octanediol vs 165.61+/-23.35 mg/g dry weight for standard (p<0.0001). Differences were also detected at X-ray (mean score 0.7+/-0.6 octanediol vs 3.8+/-0.4 standard at 75 days). Equally, mean P content was 11.69+/-21.33 mg/g dry weight for standard vs 0.60+/-1.45 mg/g dry weight for octanediol samples at 30 days, and 90.90+/-12.61 mg/g dry weight for standard vs 1.42+/-4.34 mg/g dry weight for octanediol at 75 days (p<0.0001). At electron microscopy collagen appeared well preserved regardless of the type of treatment; in octanediol treated pericardium cell membranes almost disappeared and only few profiles of endoplasmic reticulum and rare mitochondria were visible. CONCLUSIONS: Treatment with octanediol strongly prevents calcification of glutaraldehyde fixed bovine pericardium in rat subdermal model, even in the long-term. Evidence of octanediol efficacy may entail important implications for new generation bioprosthetic valves.


Assuntos
Calcinose/prevenção & controle , Fixadores/toxicidade , Glutaral/toxicidade , Octanóis/uso terapêutico , Pericárdio/transplante , Animais , Bioprótese , Calcinose/induzido quimicamente , Calcinose/metabolismo , Calcinose/patologia , Cálcio/metabolismo , Bovinos , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos/métodos , Microscopia Eletrônica , Pericárdio/metabolismo , Pericárdio/ultraestrutura , Fósforo/metabolismo , Ratos , Ratos Sprague-Dawley , Transplante Heterólogo
10.
Cancer Sci ; 98(6): 795-802, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17433036

RESUMO

In the course of screening for anticancer agents, a novel active compound, F3-2-5, was isolated from culture broth of Streptomyces sp., KACC91015. Its structure was identified using nuclear magnetic resonance, mass spectrometry, and molecular modeling experiments, and confirmed by total synthesis. The growth of various human cancer cell lines was inhibited in a dose-dependent manner by 0.06-0.48 mM F3-2-5 over 24 h. Its IC(50) values were estimated at 37 microM on HeLa, 72 microM on A549, and 190 microM on HT-29 cells. However, F3-2-5 had no antiproliferative effect on normal lymphocytes and normal fibroblasts used as controls. Moreover, it affected cell cycle regulation and caused apoptosis of the HeLa cells; chromatin condensation and DNA fragmentation were observed in cells exposed to 80 microM F3-2-5. Western blot analysis revealed that F3-2-5 inhibited phosphorylation of retinoblastoma protein (pRb) and reduced expression of cyclin-dependent kinase-4 and -6, and cyclin D1 and E, while levels of p53 and p21(WAF1/CIP1) increased. Taken together, these findings show that F3-2-5 inhibits proliferation of HeLa cells by inducing G(1) phase arrest as a consequence of inhibition of pRb phosphorylation following up-regulation of p21(WAF1/CIP1) and p53. Furthermore, apoptosis in HeLa cells treated with F3-2-5 was associated with an increase in Bax and p53, leading to release of cytochrome c, activation of caspase-3, and -8, and cleavage of poly (ADP-ribose) polymerase.


Assuntos
Antineoplásicos/uso terapêutico , Apoptose/efeitos dos fármacos , Fase G1/efeitos dos fármacos , Octanóis/uso terapêutico , Streptomyces/química , Antineoplásicos/farmacologia , Proliferação de Células/efeitos dos fármacos , Células HeLa , Humanos , Octanóis/isolamento & purificação , Fosforilação , Proteína do Retinoblastoma/metabolismo , Proteína Supressora de Tumor p53/metabolismo
11.
Epilepsy Res ; 71(2-3): 188-94, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16875800

RESUMO

The common features of all types of epilepsy are the synchronized and uncontrolled discharges of nerve cell assemblies. The reason for the pathologically synchronized discharges of the neuron is not exactly known yet. Recent reports claim that gap junctions have a critical role in neuronal synchronization. The present study was planned to investigate the effects of octanol, a gap junction blocker, on penicillin-induced experimental epilepsy. Permanent screw electrodes allowing EEG monitoring from conscious animals and permanent cannula providing the administration of the substances to the brain ventricle were placed into the cranium of rats under general anesthesia. After the postoperative recovery period, epileptiform activity was generated by injecting 300 IU crystallized penicillin through the ventricular cannula. When epileptiform activity, monitored from a digital recording system, reached at its maximum intensity, octanol was applied in the same way as penicillin administered. Application of octanol caused an inhibition in the epileptiform activity. Vehicle solution alone did not affect the epileptiform activity. Results of this study suggest that the blockade of electrical synapses may contribute to the prevention and amelioration of epileptic activity. Production of gap junction blockers selective for connexin types is needed. Further studies on the differential roles of gap junctions on certain epileptiform activities are required.


Assuntos
Anticonvulsivantes/farmacologia , Eletroencefalografia/efeitos dos fármacos , Octanóis/farmacologia , Convulsões/fisiopatologia , Animais , Anticonvulsivantes/uso terapêutico , Relação Dose-Resposta a Droga , Eletrodos Implantados , Masculino , Octanóis/uso terapêutico , Penicilina G , Ratos , Ratos Wistar , Convulsões/induzido quimicamente , Convulsões/tratamento farmacológico
12.
J Pharm Pharm Sci ; 8(3): 578-85, 2005 Oct 28.
Artigo em Inglês | MEDLINE | ID: mdl-16401404

RESUMO

PURPOSE: New 2-azabicyclo[3.2.2]nonanes were prepared from antiprotozoal bicyclo[2.2.2]octan-2-ones to investigate the influence of the replacement of the rigid bicyclo-octane structure by the more flexible bicyclo-nonane system on the antiplasmodial and antitrypanosomal activity. METHODS: The 2-azabicyclo[3.2.2]nonanes were synthesized via a one-step procedure from bicyclo[2.2.2]octan-2-ones and tested for their activities against Trypanosoma b. rhodesiense and Plasmodium falciparum K1 (resistant to chloroquine and pyrimethamine) using in vitro microplate assays. RESULTS: 2-azabicyclo[3.2.2]non-5-ylamines exhibit higher antiprotozoal activities than 4-aminobicyclo[2.2.2]octanes, 4-aminobicycl [2.2.2]octan-2-ones and 4-amino-2-azabicyclo[3.2.2]nonan-3-ones. (7, 8-Diphenyl-2-azabicyclo[3.2.2]non-5-yl)-dimethylamine shows enhanced anti-trypanosomal (IC50 = 0.60 microM) and remarkable antiplasmodial (IC50 = 0.28 microM) activity. However, the in vivo activity of this compound against Plasmodium berghei in mice is moderate. CONCLUSIONS: Due to their promising in vitro antiprotozoal activity and their low cytotoxicity, 2-azabicyclo[3.2.2]nonanes should serve as lead compounds for further modifications.


Assuntos
Compostos Bicíclicos Heterocíclicos com Pontes/síntese química , Compostos Bicíclicos Heterocíclicos com Pontes/farmacologia , Octanóis/síntese química , Octanóis/farmacologia , Plasmodium falciparum/efeitos dos fármacos , Trypanosoma brucei rhodesiense/efeitos dos fármacos , Animais , Compostos Bicíclicos Heterocíclicos com Pontes/uso terapêutico , Células Cultivadas , Humanos , Malária Falciparum/tratamento farmacológico , Masculino , Camundongos , Octanóis/uso terapêutico , Plasmodium falciparum/fisiologia , Trypanosoma brucei rhodesiense/fisiologia , Tripanossomíase Africana/tratamento farmacológico
13.
J Neurosurg ; 87(6): 916-20, 1997 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-9384404

RESUMO

Several lines of evidence indicate that the extent of ischemic injury is not defined immediately after arterial occlusion, but that infarction expands over time. Episodes of spreading depression have been linked to this secondary increase in infarct volume. Tissue bordering the infarction fails to repolarize following spreading depression and is incorporated into the lesion. The result is that ischemic infarctions expand stepwise after each episode of spreading depression. Another line of evidence has demonstrated that gap junction blockers effectively inhibit spreading depression. These observations suggest that traffic of potentially harmful cytosolic messengers between ischemic cells and surrounding nonischemic cells might cause amplification of injury in focal stroke. It is therefore conceivable that minimizing gap junction permeability might reduce final infarct volume. To test this hypothesis, the authors pretreated rats with the gap junction blocker, octanol, before occluding the middle cerebral artery and compared the sizes of the ischemic lesions to those in rats that received the vehicle, dimethyl sulfoxide, prior to arterial occlusion. Histopathological analysis was performed 24 hours later. The 12 octanol-treated animals showed a significantly decreased mean infarction volume (80 +/- 16 mm3) compared with the nine control rats (148 +/- 9 mm3). In a separate set of experiments, the frequency of experimentally induced waves of spreading depression was evaluated after octanol treatment. Octanol pretreatment resulted in complete inhibition in two of nine animals, transient inhibition in five, and no inhibition in two. The results indicate that gap junction inhibitors, when not limited by toxicity, have significant therapeutic potential in the treatment of acute stroke.


Assuntos
Infarto Cerebral/prevenção & controle , Transtornos Cerebrovasculares/prevenção & controle , Junções Comunicantes/efeitos dos fármacos , Fármacos Neuroprotetores/uso terapêutico , Octanóis/uso terapêutico , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Encéfalo/patologia , Isquemia Encefálica/metabolismo , Isquemia Encefálica/patologia , Isquemia Encefálica/fisiopatologia , Comunicação Celular/efeitos dos fármacos , Permeabilidade da Membrana Celular/efeitos dos fármacos , Infarto Cerebral/patologia , Infarto Cerebral/fisiopatologia , Transtornos Cerebrovasculares/metabolismo , Transtornos Cerebrovasculares/patologia , Transtornos Cerebrovasculares/fisiopatologia , Citosol/efeitos dos fármacos , Citosol/metabolismo , Modelos Animais de Doenças , Potenciais Evocados/efeitos dos fármacos , Junções Comunicantes/metabolismo , Junções Comunicantes/fisiologia , Ataque Isquêmico Transitório/metabolismo , Ataque Isquêmico Transitório/patologia , Ataque Isquêmico Transitório/fisiopatologia , Masculino , Fármacos Neuroprotetores/administração & dosagem , Octanóis/administração & dosagem , Ratos , Ratos Wistar , Sistemas do Segundo Mensageiro/efeitos dos fármacos , Fatores de Tempo , Resultado do Tratamento
16.
Ann Intern Med ; 84(3): 290-2, 1976 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-1259264

RESUMO

A patient with chronic constipation developed liver injury and leukopenia following the ingestion of Doxidan, a combination drug consisting of danthron and dioctyl calcium sulfosuccinate. Evidence is presented that dioctyl calcium sulfosuccinate may have potentiated the toxicity. The liver injury was associated with deposition of IgE in the Kupffer cells. The mechanism of toxicity remains unclear.


Assuntos
Antraquinonas/efeitos adversos , Catárticos/efeitos adversos , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Fígado/efeitos dos fármacos , Succinatos/efeitos adversos , Adulto , Antraquinonas/uso terapêutico , Catárticos/uso terapêutico , Doença Hepática Induzida por Substâncias e Drogas/patologia , Constipação Intestinal/tratamento farmacológico , Combinação de Medicamentos , Feminino , Humanos , Imunoglobulina E , Leucopenia/induzido quimicamente , Fígado/patologia , Octanóis/efeitos adversos , Octanóis/uso terapêutico , Succinatos/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...